|
 |
| home > ebr > spring 2003 > meptides: a novel class of synthetic peptide derivatives for the potential treatment of neurodegenerative diseases |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| A number of seemingly unrelated neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, CJD (the human form of 'mad cow' disease) and ALS (motor neurone disease) have all recently been linked to a common pathogenic process called amyloidosis. In each case a specific protein or peptide clumps together in a specific part of the brain to form toxic soluble oligomers and/or insoluble fibres, which are widely believed to cause the progressive degeneration of neurons associated with these diseases. Several academic groups and at least one biotech company are now working on a novel class of synthetic peptide derivatives ('meptides') which can inhibit and reverse this process of protein/peptide aggregation in vitro, and which have the potential to yield effective treatments or perhaps even outright cures for all these diseases. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
CPhI Worldwide
5-7 October 2010, Paris, France
CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 25,000 industry professionals visiting some 1,430 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI.
More info >> |
|
 |
News and Press Releases |
 |
Breau Leads Bioanalytical/Analytical Division at MPI Research
MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that Alan P. Breau, PhD, has joined the company as Vice President of its Bioanalytical and Analytical Services (B/AS) division. B/AS is one of the three core research divisions at MPI Research, along with Drug Safety Evaluation and Discovery Services.
More info >> |
|
  |
